Evidence map›Paper›PMID 34630564›Full record

ArticleJournal of oncology2021

HLA-DRB1

Xu Wang, Francisco Almazan, Yoel Genaro Montoyo-Pujol, Antonia Martin-Casares, Aurelio Martin, Teresa Cabrera, Miguel Angel López-Nevot

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xu WangServicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, Avda. Fuerzas Armadas s/n, Granada 18014, Spain.ORCID https://orcid.org/0000-0003-4964-9460
Francisco AlmazanPrograma de Doctorado en Biomedicina, Universidad de Granada, Granada, Spain.ORCID https://orcid.org/0000-0002-0000-1885
Yoel Genaro Montoyo-PujolServicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, Avda. Fuerzas Armadas s/n, Granada 18014, Spain.ORCID https://orcid.org/0000-0003-3169-0924
Antonia Martin-CasaresServicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, Avda. Fuerzas Armadas s/n, Granada 18014, Spain.
Aurelio MartinServicio de Anatomía Patológica, Hospital Universitario Virgen de las Nieves, Avda. Fuerzas Armadas s/n, Granada 18014, Spain.
Teresa CabreraDepartamento Bioquímica, Biología Molecular e Inmunología III, Universidad de Granada, Granada, Spain.ORCID https://orcid.org/0000-0002-9871-1374
Miguel Angel López-NevotServicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, Avda. Fuerzas Armadas s/n, Granada 18014, Spain.ORCID https://orcid.org/0000-0002-3465-6062
Universidad de Granada · ESHospital Universitario Virgen de las Nieves · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe influence of HLA class I and II loci on the susceptibility to melanoma remains an area of intense debate. This study aimed to examine whether the HLA system was related to melanoma susceptibility and prognosis in a southern Spanish population.

methodsIn this study, HLA class I and class II genotyping were performed using polymerase chain reaction sequence-specific oligonucleotides (PCR-SSO) in 237 Spanish melanoma patients and 636 ethnically matched controls. Data were analyzed according to the clinical characteristics of the defined subgroups.

resultsCompared to the control group, DRB1

conclusionThese findings established HLA-DRB1

Identifiers

PMID34630564
PMCPMC8497119
OpenAlexW3203269307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.